KRAS and familial pancreatic carcinoma: Chan-Seng-Yue et al. demonstrate how KRAS mutant dosage defines different pancreatic cancer phenotypes; higher dosages are related to a more undifferentiated and aggressive phenotype than lower, which progress differently through the acquisition of other oncogenic gains such as MYC amplifications [16,17].